aav1/serca2a
Gene therapyexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2012 (NCT01643330)
Timeline
Indications
Mechanism of action
- Sarcoplasmic/endoplasmic reticulum calcium ATPase 2Supplementation
ATP2A2 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aav1/serca2a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06061549 | Phase 1 | Aug 24, 2023 | Sardocor Corp. |
| NCT00534703 | Phase 2 | Jul 1, 2014 | British Heart Foundation, Celladon Corporation, Leducq Foundation, University of London |
| NCT01643330 | Phase 2 | Jul 1, 2012 | Celladon Corporation |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celladon Corporation | For profit | 2 | 1 | 1 | 2012 |
| British Heart Foundation | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Leducq Foundation | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Sardocor Corp. | For profit | 1 | 1 | 1 | 2023 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2014 |
5 organizations
Page 1 / 1